Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...

Today is World Diabetes Day. Stakeholders are concerned by the growing number of people with diabetes who cannot access the ...

Nov 7(Reuters) - Insulet (PODD.O), opens new tab raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps. Shares of the medical device maker ...

Insulet’s Omnipod 5 automated insulin delivery (AID) system has multiple avenues to expand as it has revolutionized the way patients treat their diabetes, including the new indication for Type 2 ...

In September, the company said that it expects new customer additions to be stronger ... Sales of Omnipod insulin pumps came in at $533.6 million for the third quarter, compared with analysts ...

Q3 2024 Earnings Call Transcript November 6, 2024 Tandem Diabetes Care, Inc. beats earnings expectations. Reported EPS is $-0 ...

pump manufacturers, regulatory authorities, and policymakers can best ensure the safety of new and long-standing users of insulin pumps as the technology continues to develop. We gathered evidence ...

Analyst Jeff Johnson from Robert W. Baird maintained a Buy rating on Insulet (PODD – Research Report) and keeping the price target at ...

Ypsomed and CamDiab are pleased to announce the approval of mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop ...